TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16555056
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (I)
Study: 16555056
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (L+I)
Study: 8728123
Drug: 10 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 weeks of moderate dose (30 mg/d) beta‐carotene
Study: 6136286
Drug: Diisopropyl phenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diisopropyl phenol 2 mg kg‐1 i.v. bolus injection
Study: 6136286
Drug: Diisopropyl phenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diisopropyl phenol infusion (150 micrograms kg‐1 min‐1 for 30 min and 75 micrograms kg‐1 min‐1 thereafter)
Study: 6136286
Drug: Diisopropyl phenol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diisopropyl phenol infusion
Study: 25068560
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care plus placebo ultrasound treatment (PUT)
Study: 19596934
Drug: Amitriptyline (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (target dose, 100 mg daily)
Study: 12920408
Drug: Clozapine 100
Normalized name: clozapine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 100 mg/d
Study: 12920408
Drug: Clozapine 300
Normalized name: clozapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 300 mg/d
Study: 12920408
Drug: Clozapine 600
Normalized name: clozapine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine 600 mg/d
Study: 14694498
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CrM) supplementation (5 g daily)
Study: 9825105
Drug: Ofloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (400 mg orally once a day or 200 mg intravenously twice a day for 2‐4 days followed by oral use for 6‐8 days)
Study: 7621388
Drug: Clomipramine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine and behaviour therapy
Study: 25444803
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine (3.75 μg antigen with half a standard dose of MF59)
Study: 25444803
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine (7.5 μg antigen with a full dose of MF59)
Study: 25444803
Drug: Non-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted vaccine (15 μg formulation)
Study: 25444803
Drug: MF59-adjuvanted vaccine
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59-adjuvanted vaccine (3.75 μg antigen)
Study: 25444803
Drug: All A/H1N1
Approvals — FDA: no, EMA: no, PMDA: no
Description: All A/H1N1 vaccine formulations
Study: 22063370
Drug: Morphine (20mg)
Normalized name: morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine (20mg)
Study: 8287640
Drug: Mild hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypoglycaemia (3.3 mmol/l)
Study: 8287640
Drug: Mild hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypoglycaemia (3.7 mmol/l)
Study: 8287640
Drug: Moderate hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate hypoglycaemia (2.5 mmol/l) after mild hypoglycaemia
Study: 8287640
Drug: Control (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (blood glucose maintained at 4.5 mmol/l)
Study: 25110439
Drug: Cholecystokinin (CCK)
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin (CCK) administered at a dose of 3 ng/kg per min for 10 min intravenously before ESWL
Study: 18809608
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with the six-peptide melanoma vaccine
Study: 16138265
Drug: Glimepiride (1-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride (1-6 mg)
Study: 12374234
Drug: Nitrates (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrates (0.1 mg/kg)
Study: 7558945
Drug: Chemoradiotherapy (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (two cycles of cisplatin 100 mg/m2 Day 1, 5-fluorouracil 1000 mg/m2 24-h infusion Days 2, 3, and 4 before radical radiotherapy, and four cycles of postradiotherapy chemotherapy)
Study: 855810
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of lysine with 260 mg of tryptophan
Study: 855810
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of lysine with 390 mg of tryptophan
Study: 855810
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg of lysine with 520 mg of tryptophan
Study: 855810
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg of lysine with 260 mg of tryptophan
Study: 855810
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg of lysine with 390 mg of tryptophan
Study: 855810
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg of lysine with 520 mg of tryptophan
Study: 25467617
Drug: Metformin treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treated groups
Study: 23563442
Drug: Daily wear
Normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily wear (DW)
Study: 1560429
Drug: One antihypertensive
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One antihypertensive medication
Study: 25012072
Drug: Single psycho‐oncological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single psycho‐oncological therapy session
Study: 22450428
Drug: Aliskiren (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (150-300 mg/daily)
Study: 22450428
Drug: Ramipril (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5-10 mg/daily)
Study: 17139035
Drug: Olanzapine monotherapy
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olanzapine monotherapy for 1 year
Study: 17139035
Drug: Lithium monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium monotherapy for 1 year
Study: 10958077
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine (100 mg, p.o.)
Study: 10958077
Drug: Oral cocaine
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cocaine (0 mg, 25 mg, 50 mg, 100 mg, 0 mg)
Study: 9078828
Drug: Early indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early indomethacin (0.2 mg/kg intravenously at 12 postnatal hours and every 24 h for two more doses)
Study: 29595671
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (2.0 mg/kg bolus, 3.0 mg/kg/h infusion)
Study: 26551637
Drug: Allogeneic hematopoietic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic hematopoietic cell transplantation (alloHCT) as consolidation treatment in first remission for HR(FLT3‐ITD) AML
Study: 26551637
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy for HR(FLT3‐ITD) AML
Study: 25042700
Drug: Multi‐modality therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic FOLFOXIRI)
Study: 25042700
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (FOLFOXIRI alone)
Study: 22500909
Drug: Intrathecal magnesium
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal magnesium (0.5 mL magnesium 10% combined with bupivacaine 15 mg)
Study: 22500909
Drug: Intrathecal fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal fentanyl (0.5 mL fentanyl combined with bupivacaine 15 mg)
Study: 22500909
Drug: Control (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.5 mL distilled water combined with bupivacaine 15 mg)
Study: 20595645
Drug: Strawberry beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strawberry beverage (Str; containing 10 g freeze-dried fruit)
Study: 14659354
Drug: Epirubicin 60-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8, repeated every 3 weeks
Study: 14659354
Drug: Epirubicin 60-90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8
Study: 10870037
Drug: Glucagon (GLU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (GLU; 0.017 mg/kg i.m.)
Study: 10870037
Drug: Glucagon (GLU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (GLU; 0.017 mg/kg i.m.) + hCRH (2.0 µg/kg i.v.)
Study: 10870037
Drug: Glucagon (GLU;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (GLU; 0.017 mg/kg i.m.) + AVP (0.17 U/kg i.m.)
Study: 9195148
Drug: Azelastine (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine (0.56 mg bid)
Study: 9195148
Drug: Beclomethasone (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone (0.2 mg bid)
Study: 9114912
Drug: Dilevalol 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dilevalol 800 mg
Study: 3984975
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium therapy
Study: 30394834
Drug: Tightly controlled
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tightly controlled renoprotective protocol including regular clinical evaluations, blood pressure management, and glucocorticoid dose reduction if indicated.
Study: 24164309
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel (0.5% w/w), applied four times a day for 5 days
Study: 24164309
Drug: Myrrh gel
Normalized name: Myrrh
DrugBank: Myrrh (DB11605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrrh gel (0.5% w/w), applied four times a day for 5 days
Study: 24164309
Drug: Plain mucoadhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain mucoadhesive gel (placebo), applied four times a day for 5 days
Study: 22172430
Drug: 40 infusions
Normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 infusions of a multicomponent disodium EDTA chelation solution
Study: 22172430
Drug: Oral, high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, high-dose multivitamin and mineral supplement
Study: 20797891
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (preop-RT) with chemotherapy (CT)
Study: 20797891
Drug: Preoperative radiotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiotherapy (preop-RT) without chemotherapy (Control)
Study: 18402597
Drug: Regular doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular doses of CBM588
Study: 18402597
Drug: Double doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double doses of CBM588
Study: 18402597
Drug: Regular doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular doses of CBM588 (Group B)
Study: 18402597
Drug: Double doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double doses of CBM588 (Group C)
Study: 8646946
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms bolus injection)
Study: 8646946
Drug: Octreotide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (10 micrograms bolus injection)
Study: 8646946
Drug: Octreotide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (250 micrograms/hour infusion)
Study: 1655867
Drug: Intraarterial Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial Adriamycin (60 mg/m2) with lipiodol (10 ml)
Study: 1655867
Drug: Intraarterial Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial Adriamycin (60 mg/m2) without lipiodol
Study: 1655867
Drug: Intravenous Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Adriamycin (60 mg/m2)
Study: 6344591
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid therapy
Study: 31989151
Drug: roluperidone 32
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roluperidone 32 mg
Study: 31989151
Drug: roluperidone 64
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roluperidone 64 mg
Study: 28074235
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and CNS radiotherapy
Study: 28074235
Drug: Both treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both treated groups (chemotherapy alone and chemotherapy with CNS radiotherapy)
Study: 26022945
Drug: CPAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP treatment for 3 months
Study: 26022945
Drug: No CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CPAP treatment for 3 months
Study: 23143842
Drug: Co-trimoxazole 960
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-trimoxazole 960 mg twice daily
Study: 15918064
Drug: Viscoseal (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscoseal (10 ml)
Study: 10908002
Drug: Matrix model,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matrix model, a manualized program of intensive outpatient treatment
Study: 8455074
Drug: Erythromycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (3 mg.kg-1 i.v. over 20 min)
Study: 3778565
Drug: 60‐mg urapidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60‐mg urapidil slow release‐capsule
Study: 3778565
Drug: 30‐mg urapidil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30‐mg urapidil drinking ampoule (Ebrantil)
Study: 12422059
Drug: Nortriptyline (targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (targeted to 190-570 nmol/l)
Study: 9589267
Drug: Naloxone 0.5
Normalized name: naloxone 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 0.5 mg
Study: 9589267
Drug: Buprenorphine 2
Normalized name: buprenorphine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine 2 mg/naloxone 0.5 mg
Study: 8024075
Drug: Mefloquine (1,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine (1,250 mg divided between two doses of 750 and 500 mg six hours apart) plus doxycycline (200 mg once a day for seven days)
Study: 8024075
Drug: Artesunate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (300 mg total for 2.5 days; 100 mg followed by 50 mg every 12 hr for 2.5 days) plus doxycycline (200 mg once a day for seven days)
Study: 19622463
Drug: Rituximab 375
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 375 mg/m², Cyclophosphamide 1000 mg/m², Vincristine 1.4 mg/m² (max 2 mg), Prednisone 50 mg every other day for 30 days, G-CSF on days 7-10 after each cycle
Study: 15548216
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic cream (EMLA) applied for forearm skin anaesthesia
Study: 15548216
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic cream (EMLA)
Study: 26936358
Drug: 1200 mg/d
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/d ibuprofen (IBU)
Study: 24734285
Drug: SQ-standardized subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-standardized subcutaneous immunotherapy (SCIT)
Study: 24734285
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy tablets (SLIT tablet)
Study: 24734285
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (neither SCIT nor SLIT tablet)
Study: 20110249
Drug: Cinacalcet (30‐180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30‐180 mg/day) plus low‐dose active vitamin D
Study: 20110249
Drug: Flexible dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dosing of active vitamin D alone
Study: 18427279
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg/d
Study: 1854570
Drug: Diuretics plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics plus enalapril or captopril (group 2)
Study: 1854570
Drug: Diuretics alone
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics alone (group 1)
Study: 6315227
Drug: Continuous chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chemotherapy (1‐(2‐chloroethyl‐3‐cyclohexyl‐1‐nitrosourea, cyclophosphamide, methotrexate, and vincristine followed by 4'‐demethylepipodophyllotoxin 9‐[4,6‐O‐(R) ethylidene‐beta‐D‐glucopyranoside] and doxorubicin at progression of disease)
Study: 6315227
Drug: Alternating chemotherapy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating chemotherapy (alternating the same drugs as continuous)
Study: 15759946
Drug: 3 MU
Normalized name: Orasep Reformulated Dec 2013 Mucosal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Study: 15759946
Drug: 6 MU
Normalized name: Pancrelipase 16 mu
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 MU daily interferon (IFN)‐alpha‐2a monotherapy for 12 months
Study: 10487369
Drug: Carbohydrate-electrolyte solution
Normalized name: CARBOHYDRATE/ELECTROLYTES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate-electrolyte solution (CHO-E)
Study: 7729608
Drug: 6-h clamped
Normalized name: CLAMP,BAG H#7765
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-h clamped hyperglycemia (PG approximately 13.5 mmol/l)
Study: 7729608
Drug: Nocturnal hyperglycemia
Normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nocturnal hyperglycemia (PG approximately 13.5 mmol/l)
Study: 7729608
Drug: Euglycemia (PG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia (PG approximately 5 mmol/l)
Study: 7729608
Drug: 15 h
Normalized name: PEG-15 hydroxystearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 h of euglycemia (approximately 5 mmol/l)
Study: 7729608
Drug: 15 h
Normalized name: PEG-15 hydroxystearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 h of hyperglycemia (approximately 17 mmol/l)
Study: 30292850
Drug: Once-daily (OD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily (OD) PCI
Study: 30292850
Drug: Twice-daily (BD)
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily (BD) PCI
Study: 30292850
Drug: Delay between
Normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay between end of chemotherapy and PCI
Study: 29258763
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of intravenous dexamethasone and 1 dose of normal saline (Group B)
Study: 29258763
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of intravenous dexamethasone (Group C)
Study: 29258763
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of normal saline (Group A)
Study: 26419487
Drug: Pregabalin and
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin and celecoxib combination
Study: 25287827
Drug: Dabrafenib and
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib and trametinib (combination therapy)
Study: 8933665
Drug: Anti-pertussis vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-pertussis vaccines
Study: 1540362
Drug: Labetalol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (0.4 mg/kg)
Study: 3546255
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral meclofenamate during the follicular phase
Study: 3546255
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral meclofenamate during the luteal phase
Study: 3546255
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg inhaled metaproterenol
Study: 20078609
Drug: Sitaxentan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxentan 100 mg daily for 7 days
Study: 24656288
Drug: Sitaxentan 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitaxentan 100 mg
Study: 17686882
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E(2)) administration
Study: 17686882
Drug: L-arginine/GHRP-2 stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine/GHRP-2 stimulation
Study: 17686882
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (E(2))
Study: 17686882
Drug: L-arginine/GHRH stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine/GHRH stimulation